An assay (test) developed at NCATS helped a research team identify a potential new drug target to treat a neurological disorder, called Charcot-Marie-Tooth disease.
Read about a screening technology that has helped researchers identify a potential new drug target for Charcot-Marie-Tooth disease, a collaboration using patient registry software, and more.
Bridging Interventional Development Gaps researchers will support two projects aimed at finding treatments for diabetic keratopathy — a condition that often leads to blindness — and severe heart attacks.
NCATS researchers will begin work on three new pre-clinical drug development projects for malaria, Lassa fever and two blood disorders through the Therapeutics for Rare and Neglected Diseases program.
How is NCATS advancing translational research? Learn more about the Center's work and some of its early successes.
MORE CENTER NEWS
Rare Diseases Clinical Research Network expands to 22 consortia and a data center.
Eleven institutions will refine 3-D human tissue chips to test the safety of drugs.
- Publication of Notice of Proposed Rulemaking for Clinical Trials Registration and Results Submission under FDAAA
- NIH Request for Public Comments on the Draft NIH Policy on Dissemination of NIH-Funded Clinical Trial Information
- Request for Information (RFI): Input on Direction of the Second Phase of the "Illuminating the Druggable Genome" Program
- More Funding & Notices...
- Providers' Perspectives on Male Involvement in Family Planning in the Context of a Cluster-Randomized Controlled Trial • AIDS Care
- Narrow Time Window Exists to Start HIV Therapy, Study Shows • EurekAlert!/University of Texas Health Science Center at San Antonio
- Obese Children Burdened by More than Weight • University of San Diego
- More News & Events...
IN THE SPOTLIGHT
Small Business Funding Opportunities
NCATS participates in the Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs to support companies developing new therapies and diagnostics to help move bench research to clinical practice and commercialization.